Effect of Proprietary Chinese Medicine on Coronary Microvascular Dysfunction in Patients with Microvascular Angina: A Systematic Review and Meta-Analysis

Table 4

Subgroup analysis of TET based on dosage form, drug, sample size, treatment duration, sex ratio, average age, and location.

Items	Subgroup	N	SMD (95% CI)	I ^2 (%)	z
Dosage form	Pill	1	0.24 (−0.28, 0.77)	—	0.907	0.364
	Dropping pill	3	0.58 (0.30, 0.85)	28.7	4.105	<0.001
	Capsule	4	2.68 (0.75, 4.60)	97.4	2.726	0.006
Drug	TXLC	2	0.76 (−0.59, 2.10)	90.4	1.105	0.269
	STDP	2	0.63 (0.12, 1.15)	49.5	2.402	0.016
Sample size	≥80	4	2.57 (1.01, 4.14)	97.9	3.217	0.001
	<80	4	0.52 (−0.12, 1.16)	79.3	1.595	0.111
Treatment duration	≥6 months	2	0.93 (0.01, 1.85)	89.2	1.982	0.047
	<6 months	6	1.74 (0.46, 3.01)	96.7	2.663	0.008
Sex ratio	F/M ≥ 100%	7	1.68 (0.60, 2.74)	96.1	3.065	0.002
	F/M < 100%	1	0.49 (0.20, 0.77)	—	3.349	0.001
Average age	>60	2	0.64 (0.29, 0.98)	50.6	3.634	<0.001
	<60	5	2.19 (0.59, 3.79)	97.0	2.678	0.007
Location	North	4	0.96 (0.15, 1.77)	93.8	2.327	0.020
	South	4	2.19 (0.04, 4.35)	97.4	1.922	0.046